Statistics from Altmetric.com
I congratulate the research team from Rotterdam for the high-quality study design of the treatment in the Rotterdam Early Arthritis Cohort (tREACH) study, but their conclusions are overstated.1 Their quotation of the literature is incomplete, referring to some studies of initial combination disease-modifying antirheumatic drugs (DMARDs) plus corticosteroid (BeSt, FinRACo, COBRA trial) but excluding some other studies that do not support their conclusions. There have been two previously published randomised controlled trials comparing the step-up and initial combination triple DMARD therapy, which show no sustained benefit of the initial …
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.